BIOMARIN PHARMACEUTICAL INC

NASDAQ: BMRN (BioMarin Pharmaceutical Inc.)

Last update: yesterday, 3:14AM

61.42

-0.01 (-0.02%)

Previous Close 61.43
Volume 5,206,690
Avg. Volume (3M) 2,216,528
Market Cap 11,896,730,624
Price / Earnings (TTM) 158.14
Price / Earnings (Forward) 9.31
Price / Sales 3.29
Price / Book 1.90
52 Weeks Range
49.26 (-19%) — 70.98 (15%)
Earnings Date 2 Nov 2026
Profit Margin -0.52%
Operating Margin (TTM) 16.34%
Diluted EPS (TTM) -0.100
Quarterly Revenue Growth (YOY) 32.00%
Quarterly Earnings Growth (YOY) 109.40%
Total Debt/Equity (MRQ) 66.98%
Current Ratio (MRQ) 2.44
Operating Cash Flow (TTM) 676.62 M
Levered Free Cash Flow (TTM) -16.04 M
Return on Assets (TTM) 3.89%
Return on Equity (TTM) -0.31%

AIStockmoo Score

0.0
Cheaper than its usual valuation. Counted for less, as it made a loss in recent years. info
Earns below its cost of capital. Returns on capital rising. info
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
No clear trend over the past year. Somewhat below its 52-week high. info
No clear trend: the price is moving around its moving averages. It is close to them. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Holdings' Sentiment info NA
Institutions net +0.87% of shares in their latest 13F filings: 301 holders increased, 266 decreased (quarter to 30 Sep 2026). info
Short interest +43.0% from 31 Aug to 30 Oct 2026, 5.8 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
No pillar has a clear reading, so the score is unchanged.
Earnings per share have risen every year. Made a loss in recent years. info
Near its medium-term trend line. info
Price is high against its 52-week average. Down over 5 years. info
Short-term momentum rising. info
Price is near support. info
Final Score 0.02
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock BioMarin Pharmaceutical Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
BMRN 12 B - 158.14 1.90 0.0
ROIV 28 B - - 6.97 1.0
INCY 23 B - 58.48 4.26 0.7
SYRE 9 B - - 10.08 1.1
MDGL 9 B - - 14.74 -0.4
CORT 7 B - 47.78 8.89 -1.5

Select this tab to load the latest available analysis.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Sector Healthcare
Industry Biotechnology
Investment Style Mid Growth
% Held by Insiders 0.38%
% Held by Institutions 103.99%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 110.75%

Positions Holders Shares
Increased 301 20,250,655
Decreased 266 18,634,244
New 90 3,927,888
Sold out 77 3,856,889

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 14,122,815 5.8
15 Oct 2026 12,050,657 4.9
30 Sep 2026 11,522,835 5.5
15 Sep 2026 10,075,655 5.5
31 Aug 2026 9,877,553 5.8
14 Aug 2026 10,202,950 3.7

FINRA short interest via Nasdaq, reported twice a month.

5 Positive 4 Negative 9 Neutral
Date Type Details
19 Nov 2026 Yahoo Finance BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount
BioMarin Pharmaceutical (NASDAQ:BMRN) is betting that a growing rare-disease pipeline and its integration of Amicus will help sustain growth, as executives seek to address investor concerns about competition for its VOXZOGO treatment. The company expects revenue of $3.8 billion to $3.9 billion in 2…
18 Nov 2026 Yahoo Finance How Investors Are Reacting To BioMarin (BMRN) Acquired Drug Growth Prospects
BioMarin Pharmaceutical scheduled three investor conference appearances in November 2026 in New York and London, highlighting its rare-disease portfolio and development pipeline to a global healthcare audience. Management highlighted up to US$2.6b in peak annual sales potential from acquired Amicus…
16 Nov 2026 Yahoo Finance BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
BioMarin Pharmaceutical (NASDAQ:BMRN) expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference. Hardy said the company’s global…
11 Nov 2026 Yahoo Finance BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
BioMarin Pharmaceutical (NASDAQ:BMRN) is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion. Chief Financial Officer Brian Mueller said third-quarter revenue rose 32% to $1 bi…
04 Nov 2026 Yahoo Finance BioMarin to Participate in Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.
03 Nov 2026 Yahoo Finance BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ...
BioMarin Pharmaceutical Inc (BMRN) topped $1 billion in quarterly revenue for the first time with 32% growth, but trimmed full-year 2026 guidance on order timing and Middle East disruption.
03 Nov 2026 Yahoo Finance BioMarin Pharmaceutical Inc. Q3 2026 Earnings Call Summary
Moby summary of BioMarin Pharmaceutical Inc.'s Q3 2026 earnings call…
03 Nov 2026 Yahoo Finance BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported third-quarter revenue above Wall Street expectations, supported by stronger-than-anticipated sales across several treatments for rare diseases.
02 Nov 2026 Yahoo Finance BioMarin (BMRN) Q3 2026 Earnings Call Transcript
Revenue topped $1 billion for first time, fueled by Amicus integration.
02 Nov 2026 Yahoo Finance BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic condit…
02 Nov 2026 Yahoo Finance BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut
BioMarin Pharmaceutical (BMRN) is back in focus after a mixed Q3 2026 update, with adjusted profit topping analyst expectations while sales came in slightly below forecasts and full year guidance moved lower. Recent trading tells a mixed story for BioMarin Pharmaceutical. The share price slipped…
02 Nov 2026 Yahoo Finance BioMarin (BMRN) Stock May Be A Bargain After Fabry Therapy Deal
BioMarin Pharmaceutical has been busy, with a large acquisition, fresh Fabry disease assets and a stock price that is still down over the longer stretch, which naturally raises a question about how much investors are paying today for the company’s sales base. For anyone tracking rare disease drug…
02 Nov 2026 Yahoo Finance BioMarin: Q3 Earnings Snapshot
(AP) — BioMarin Pharmaceutical Inc. (BMRN) on Monday reported a loss of $122…
02 Nov 2026 Yahoo Finance BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
02 Nov 2026 Yahoo Finance BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of +355.56% and -0.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
02 Nov 2026 Yahoo Finance BioMarin Pharmaceutical (NASDAQ:BMRN) reports Q3 2026 in line with expectations but full-year sales guidance misses expectations
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 2026, with revenue up 32% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $3.85 billion at the midpoint came in 1.8% below analysts’ consensus estimates.…
02 Nov 2026 Yahoo Finance BioMarin Reports Third Quarter 2026 Financial and Operating Results
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026…
01 Nov 2026 Yahoo Finance BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know.
30 Oct 2026 Yahoo Finance Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.
29 Oct 2026 Yahoo Finance Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of October 28th 2026. EXEL’s trailing and forward P/E were 20.62 and 15.25…
Show more

Recent Signals candle patterns and EMA crosses

▼ Death cross 10 sessions ago · 05 Nov
Long term · EMA 50/200
The 50-day EMA crossed below the 200-day, a widely watched sign that the long-term trend has turned down.

Technical Setup Medium

Trend order –
Slope
Entry
Volume
No clear trend: the price is moving around its moving averages. It is close to them.
Nearest support: 60.15 – 61.20 · strong level
Nearest resistance: 61.48 – 62.46 · weak level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria